A Cost Decision Analysis for Diagnosing and Staging

  • Stephan L. Haas
  • Konstantin von Heydwolff
  • J.-Matthias Löhr
Part of the Medical Radiology book series (MEDRAD)


Diagnostic technologies have no major contributory role in the observed continuous increase in health care spendings of Western societies. Although cost-benefit analyses were mainly performed to evaluate therapeutic interventions, the evaluation of different diagnostic procedures became the focus of health technology assessments in recent years. So-called decision trees proved to be a valuable tool for studying cost-effectiveness.

On average 4,000 € have to be spent each month for a patient with pancreatic cancer (PC) when indirect costs are included. Diagnostic imaging accounts for 9% of all costs during hospitalisation.

In more than 80% of PC patients a combination of abdominal US and CT clearly defines the locally progressed or even metastasized state and is associated with limited costs. According to cost-effectiveness models, the combination of CT with EUS, EUS-FNA or laparoscopy was associated with higher costs for diagnosis and staging but reduced total costs by avoiding unnecessary laparotomies in patients with peritoneal carcinomatosis or non-locoregional lymph node metastases. Further studies have to prove cost-effectiveness when state of the art multidetector row CT scanners with very high accuracy rates are combined with complimentary diagnostic modalities.

Screening for pancreatic cancer in high risk populations (familial pancreatic cancer families, hereditary pancreatitis, Peutz-Jeghers syndrome) offers the possibility to detect (pre)malignant pancreatic lesions at an early stage when a curative resection is still possible. Studies demonstrated that screening might be cost-effective only in subgroups of patients with the highest cancer risk. EUS-based screening programmes are hampered by a significant number of false-positive results leading to unnecessary diagnostic and therapeutic procedures contributing to high expenditures.


Pancreatic Cancer Health Technology Assessment Intraductal Papillary Mucinous Neoplasm Intraductal Papillary Mucinous Neoplasm Resectable Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Computed tomography


Multidetector-row computed tomography


Endoscopic ultrasound


Fine needle


Fine needle aspiration


Incremental cost effectiveness ratio


Magnetic resonance imaging


Pancreatic cancer




  1. Abelson J, Giacomini M, Lehoux P, Gauvin FP (2007) Bringing ‘the public’ into health technology assessment and coverage policy decisions: from principles to practice. Health Policy 82:37–50PubMedCrossRefGoogle Scholar
  2. Alvarez C, Livingston EH, Ashley SW, Schwarz M, Reber HA (1993) Cost-benefit analysis of the work-up for pancreatic cancer. Am J Surg 165:53–58PubMedCrossRefGoogle Scholar
  3. Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53:941–973Google Scholar
  4. Barone JE (2008) Pancreaticoduodenectomy for presumed pancreatic cancer. Surg Oncol 17:139–144PubMedCrossRefGoogle Scholar
  5. Beinfeld MT, Gazelle GS (2005) Diagnostic imaging costs: are they driving up the costs of hospital care? Radiology 235:934–939PubMedCrossRefGoogle Scholar
  6. Beinfeld MT, Wittenberg E, Gazelle GS (2005) Cost-effectiveness of whole-body CT screening. Radiology 234:415–422PubMedCrossRefGoogle Scholar
  7. Bosanquet N, Sikora K (2004) The economics of cancer care in the UK. Lancet Oncol 5:568–574PubMedCrossRefGoogle Scholar
  8. Böttger TC, Boddin J, Düber C, Heintz A, Küchle R, Junginger T (1998) Diagnosing and staging of pancreatic carcinoma – what is necessary? Oncology 55:122–129PubMedCrossRefGoogle Scholar
  9. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI, Participants of the Fourth International Symposium of Inherited Diseases of the Pancreas (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460–1469PubMedCentralPubMedCrossRefGoogle Scholar
  10. Del Chiaro M, Zerbi A, Capurso G, Zamboni G, Maisonneuve P, Presciuttini S, Arcidiacono PG, Calculli L, Falconi M (2010) Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. Dig Liver Dis 42:597–605PubMedCrossRefGoogle Scholar
  11. Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF (2000) Cost analysis of pancreatic carcinoma treatment. Cancer 89:1917–1924PubMedCrossRefGoogle Scholar
  12. Eddama O, Coast J (2008) A systematic review of the use of economic evaluation in local decision-making. Health Policy 86:129–141PubMedCrossRefGoogle Scholar
  13. Elixhauser A, Halpern MT (1999) Economic evaluations of gastric and pancreatic cancer. Hepatogastroenterology 46:1206–1213PubMedGoogle Scholar
  14. Fineberg HV (1980) Decision trees. Construction, uses, and limits. Bull Cancer 67:395–404PubMedGoogle Scholar
  15. Furukawa H, Okada S, Saisho H, Ariyama J, Karasawa E, Nakaizumi A, Nakazawa S, Murakami K, Kakizoe T (1996) Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 78:986–990PubMedCrossRefGoogle Scholar
  16. Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, Chari ST (2004) Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol 182:897–903PubMedCrossRefGoogle Scholar
  17. Goh BK (2006) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 243:709–710PubMedCentralPubMedCrossRefGoogle Scholar
  18. Harewood GC, Wiersema MJ (2001) A cost analysis of endoscopic ultrasound in the evaluation of pancreatic head adenocarcinoma. Am J Gastroenterol 96:2651–2656PubMedCrossRefGoogle Scholar
  19. Heinrich S, Goerres GW, Schäfer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235–243PubMedCentralPubMedCrossRefGoogle Scholar
  20. Hjelmgren J, Ceberg J, Persson U, Alvegård TA (2003) The cost of treating pancreatic cancer – a cohort study based on patients’ records from four hospitals in Sweden. Acta Oncol 42:218–226PubMedCrossRefGoogle Scholar
  21. Ishii H, Furuse J, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Nakachi K, Suzuki E, Yoshino M (2005) Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. Jpn J Clin Oncol 35:526–530PubMedCrossRefGoogle Scholar
  22. Ishikawa O, Ohigashi H, Imaoka S, Nakaizumi A, Uehara H, Kitamura T, Kuroda C (1999) Minute carcinoma of the pancreas measuring 1 cm or less in diameter – collective review of Japanese case reports. Hepatogastroenterology 46:8–15PubMedGoogle Scholar
  23. Keehan S, Sisko A, Truffer C, Smith S, Cowan C, Poisal J, Clemens MK, National Health Expenditure Accounts Projections Team (2008) Health spending projections through 2017: the baby-boom generation is coming to Medicare. Health Aff (Millwood) 27:w145–55CrossRefGoogle Scholar
  24. Larghi A, Verna EC, Lecca PG, Costamagna G (2009) Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res 15:1907–1914PubMedCrossRefGoogle Scholar
  25. Latchford A, Greenhalf W, Vitone LJ, Neoptolemos JP, Lancaster GA, Phillips RK (2006) Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg 93:1446–1455PubMedCrossRefGoogle Scholar
  26. McMahon PM, Halpern EF, Fernandez-del Castillo C, Clark JW, Gazelle GS (2001) Pancreatic cancer: cost-effectiveness of imaging technologies for assessing resectability. Radiology 221:93–106PubMedCrossRefGoogle Scholar
  27. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, Ubel PA, Schnipper LE, American Society of Clinical Oncology (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868–3874PubMedCrossRefGoogle Scholar
  28. Müller-Nordhorn J, Brüggenjürgen B, Böhmig M, Selim D, Reich A, Noesselt L, Roll S, Wiedenmann B, Willich SN (2005) Direct and indirect costs in a prospective cohort of patients with pancreatic cancer. Aliment Pharmacol Ther 22:405–415PubMedCrossRefGoogle Scholar
  29. Neymark N (1999a) Techniques for health economics analysis in oncology: Part 1. Crit Rev Oncol Hematol 30:1–11PubMedCrossRefGoogle Scholar
  30. Neymark N (1999b) Techniques for health economics analysis in oncology: part 2. Crit Rev Oncol Hematol 30:13–24PubMedCrossRefGoogle Scholar
  31. Plevritis SK (2005) Decision analysis and simulation modeling for evaluating diagnostic tests on the basis of patient outcomes. AJR Am J Roentgenol 185:581–590PubMedCrossRefGoogle Scholar
  32. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA (2003) Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 57:23–29PubMedCrossRefGoogle Scholar
  33. Shimizu Y, Yasui K, Matsueda K, Yanagisawa A, Yamao K (2005) Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 20:1591–1594PubMedCrossRefGoogle Scholar
  34. Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Ginès MA, Real MI, Gilabert R, Quintó L, Trilla A, Feu F, Montanyà X, Fernández-Cruz L, Navarro S (2004) Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 99:492–501PubMedCrossRefGoogle Scholar
  35. Tappenden P, Jones R, Paisley S, Carroll C (2007) The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 43:2487–2494PubMedCrossRefGoogle Scholar
  36. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, Yamaguchi T, Izawa K, Tsunoda T, Yoshino R et al (1986) Collective review of small carcinomas of the pancreas. Ann Surg 203:77–81PubMedCentralPubMedCrossRefGoogle Scholar
  37. van der Schueren E, Kesteloot K, Cleemput I (2000) Economic evaluation in cancer care: questions and answers on how to alleviate conflicts between rising needs and expectations and tightening budgets. Eur J Cancer 36:13–36, Federation of European Cancer Societies. Full reportPubMedCrossRefGoogle Scholar
  38. Vitone LJ, Greenhalf W, McFaul CD, Ghaneh P, Neoptolemos JP (2006) The inherited genetics of pancreatic cancer and prospects for secondary screening. Best Pract Res Clin Gastroenterol 20:253–283PubMedCrossRefGoogle Scholar
  39. Waugh N (2006) Health technology assessment in cancer: a personal view from public health. Eur J Cancer 42:2876–2880PubMedCrossRefGoogle Scholar
  40. Wilson LS, Lightwood JM (1999) Pancreatic cancer: total costs and utilization of health services. J Surg Oncol 71:171–181PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2010

Authors and Affiliations

  • Stephan L. Haas
    • 1
  • Konstantin von Heydwolff
    • 2
  • J.-Matthias Löhr
    • 3
  1. 1.Department of Medicine II, Gastroenterology and Oncology, Klinikum AschaffenburgTeaching Hospital of the University of WürzburgAschaffenburgGermany
  2. 2.Financial Controlling UnitTeaching Hospital of the University of WürzburgAschaffenburgGermany
  3. 3.CLINTEC, K53; Department of Surgical GastroenterologyKarolinska University Hospital HuddingeStockholmSweden

Personalised recommendations